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The increase of immunization against blood group antigens has 
reinforced the need for automated extensive blood typing. The 
aim of this study was to assess both the validity and reliability 
of red blood cell (RBC) automated agglutination technology in 
testing for antigens of Kidd (Jk), Duffy (Fy), and MNS (Ss) blood 
systems. ORTHO Sera (Ortho Clinical Diagnostics, Raritan, NJ) 
anti-Jka, anti-Jkb, Anti-Fya, anti-Fyb, anti-S, and anti-s reagents 
were each tested on RBC samples previously typed. Replicates 
were performed on three separate testing sessions with three 
consecutive repetitions within each session, thus obtaining 
486 test results. Accuracy was assessed by aggregate analysis 
of sensitivity, specificity, and area under the receiver operating 
characteristics curve (AUC). Reliability was estimated by a 
cross-classified mixed-effect logistic model. All reagents tested 
yielded optimal accuracy (100% for sensitivity and specificity, 
and 1.00 for AUC), except for anti-S, for which performance 
was slightly lower (98%, 100%, and 0.99, respectively), owing to 
misclassification of one sample in a single replicate. Anomalous 
automated measurements were recorded in 38 of 486 tests (7.8%), 
which then needed additional manual interpretation. Different 
sessions and samples were the major contributors to measurement 
failures (38% and 18%, separately). Order of repetitions and 
antigen specificity across replicates did not contribute to the 
risk of failures, although weak evidence of enhanced risk (p < 
0.10) was observed with Jk testing. Automated RBC typing with 
ORTHO Sera reagents against antigens in the Kidd, Duffy, and 
MNS blood group systems displayed nearly 100 percent accuracy. 
However, a sizable number of replicates needed additional ad 
hoc interpretation, thus suggesting that the reliability could still 
be improved. Automated agglutination technology represents 
a viable option for phenotyping large volumes of samples. 
Immunohematology 2018;34:140–147.
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Allogeneic red blood cell (RBC) transfusions remain 
an essential part of supportive treatment in patients with 
hemoglobinopathies,1 but they expose these patients to the risk 
of developing antibodies against foreign RBC antigens. The 
development of alloantibodies against RBCs may complicate 
transfusion therapy, causing hemolytic transfusion reactions, 
and present a challenge for finding compatible blood and for 
RBC crossmatching, thus ultimately jeopardizing transfusion 
safety. The frequency of alloimmunization is variable among 
patients—for example, it is apparently higher in patients with 
sickle cell disease than in individuals with myelodysplastic 
syndromes.2 The risk of alloimmunization increases in 
parallel with the number of units transfused and is also higher 
in patients with previous alloimmunization.2–4 The most 
frequent RBC alloantibodies are directed towards antigens 
in the Rh and Kell blood group systems.5 The standards of 
the Italian Society of Immunohematology and Transfusion 
Medicine require all blood donors to be typed for extended 
antigens in the Rh and Kell systems,6 which is necessary for 
transfusion support of patients with hemoglobinopathies.1 
Although this preventive measure has certainly contributed 
to lowering the risk of immunization against these antigens, 
the risk of immunization against other blood group antigens 
(e.g., Kidd [Jk], Duffy [Fy], and MNS [Ss]) persists.7 When 
available donors who have been previously phenotyped for 
these antigens are lacking, managing immunized patients 
undergoing recurrent transfusions is challenging.2
Fewer than 1 in 500 white donors might be compatible 
with recipients having an antibody mixture of anti-c/E, 
anti-S, and anti-Jka.8 Moreover, the increasing migration of 
people from Africa towards southern European countries 
will contribute to an increase in the number of patients with 
mixtures of specific antigen combinations. For instance, 60–
70 percent of individuals migrating from sub-Saharan African 
regions do not express Fy antigens, which are instead present 
in higher percentages in individuals of European origin.8
A large array of automated systems is now available for 
serologic testing in transfusion services.9–11 Fully automated 
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analyzers are essential components of many laboratory 
systems, and their gradual implementation into the laboratory 
routine has increased patient safety, enhanced standardization, 
and contributed to improving the workflow and reducing 
turnaround time.
ORTHO Sera (Ortho Clinical Diagnostics, Raritan, NJ) 
are sera for performing extended antigen phenotyping using 
the ORTHO BioVue System column agglutination technology 
(CAT) and are compatible for use on the fully automated ORTHO 
Analyzer (AutoVue Innova or Vision). ORTHO Sera have 
been recently introduced in our local laboratory for extended 
typing of blood donors. The adoption of a new technology or 
method in both the clinical and laboratory settings requires 
formal validation before widespread application to clinical 
practice.12 Validation is the documented evidence that the 
process, equipment, facilities, and entire system operates 
within established parameters and can perform effectively 
and reproducibly, thus generating results that meet predefined 
quality specifications.12 As part of validation, qualification is 
the action of verifying that personnel, equipment, or material 
work properly and deliver expected results.12 In 2011, the 
British Committee for Standards in Haematology Blood 
Transfusion Task Force published guidelines for test validation 
and staff qualification.13 More recently, the Italian National 
Blood Center has published new guidelines in support of 
process validation activities, entailing the collection of blood 
units and related compounds in Blood Transfusion Services.14 
Therefore, validation assesses both accuracy and reliability of 
a method. Accuracy represents a combination of sensitivity 
and specificity, which jointly provide the capability of a given 
method to generate results as close as possible to their true 
value. Reliability (i.e., precision) represents the ability of a 
method to provide similar results under equivalent (repeatability 
or intra-assay precision) or comparable (reproducibility or 
inter-assay precision) experimental conditions.
Therefore, the aim of this study was to validate the use 
of RBC automated CAT for testing Jk, Fy, and Ss blood group 
antigens using ORTHO Sera technology on the automated 
analyzer ORTHO AutoVue Innova.
Materials and Methods
Validation Plan and Study Design
According to our study design, successful validation was 
defined when the following endpoints could be satisfied:
• Accuracy: 100% sensitivity, specificity, and area under 
the receiver operating characteristics curve (AUC) 
identical to results previously obtained with the gold 
standard method (i.e., test tube).
• Reliability: confirmation of repeatability (intra-session) 
and reproducibility (inter-session).
As a secondary endpoint, we evaluated whether result 
reliability may be impaired by the following:
• Test replicate (session or repetition) or sample specificity.
• Blood group system (e.g., Kidd, Duffy, MNS).
• Antigen status (i.e., double-dose or single-dose 
phenotype).
We originally analyzed the technical aspects of validation 
by installation qualification (IQ) and operational qualification 
(OQ) of the analyzer. A performance qualification (PQ) was 
planned, by testing each variable in triplicate, as recommended 
by the Italian National Blood Center.14 The variables in our 
qualification study were the antigen statuses of Jk, Fy, and 
Ss. Therefore, three types of samples were evaluated for each 
blood system:
• Single-dose status: Jk(a+b+), Fy(a+b+), and S+s+.
• Double-dose status for antigen: Jk(a+b–), Fy(a+b–), and 
S+s–.
• Double-dose status for antithetical antigen: Jk(a–b+), 
Fy(a–b+), and S–s+.
Because of the rare prevalence of the lack of all antigens 
[Jk(a–b–), Fy(a–b–), and S–s–] in white individuals, we 
excluded these antigen combinations. In each session, positive 
controls (in either double-dose or single-dose state) were 
tested. Saline solution was used as a negative control (i.e., 
blank) to test for possible contamination. Overall, 13 samples 
(including controls) were analyzed in each session in three 
ordered repetitions, over three equivalent sessions, performed 
on separate days. Positive and negative samples were arranged 
in an alternate sequence to limit the risk of carryover. In total, 
702 tests were performed, including controls. Accuracy was 
evaluated on the 486 tests obtained from blood samples. The 
statistical analysis of reliability was performed on 324 tests, 
after excluding samples negative for the specific antigen 
(all negative samples returned negative tests), because 
their inclusion could deflate the rate of anomalous findings 
arbitrarily.
RBC Samples and Sera
RBC samples were obtained from leukoreduced packed 
RBC units resuspended in additive solution available in 
the blood bank inventory. A total of 14 units were selected 
from blood donors whose phenotype had been previously 
determined by test tube. Each RBC sample was used to test 
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one or more blood group antigens, depending on availability of 
sample units. Testing sessions were performed over 3 weeks. 
All samples were tested before the expiration date of the 
RBC units. Reagent RBC samples from identification panels 
Surgiscreen Resolve Panel A (Ortho Clinical Diagnostics), 
previously diluted up to a final concentration of 3 percent, were 
used as positive controls.
The ORTHO Sera (Ortho Clinical Diagnostics) are ready 
for use and contain sodium azide (concentration weight/volume 
<0.1%) as preservative and potentiators/bovine material. The 
ORTHO Sera characteristics are summarized in Table 1. The 
operating temperature ranged between 15°C and 30°C. The 
sera were stored between 2°C and 8°C if they could not be used 
within 8 hours. All reagents used are CE marked, conforming 
to the current European legislation.
Column Agglutination Technology and Its 
Interpretation
The ORTHO AutoVue Innova is an automated in vitro 
immunohematology analyzer that uses ORTHO BioVue 
System CAT with digital image processing. It basically 
integrates automation in multiple steps during the testing 
process, including pipetting, reagent handling, incubation, 
centrifugation, reaction grading, and interpretation by digital 
image processing and data management. In CAT, agglutinated 
RBCs are trapped above or in the column glass beads, whereas 
unagglutinated RBCs move through the column and form 
a pellet at the bottom.15 A score of positive reactions can be 
assigned for CAT, with a maximum value of 4 when most of 
the RBCs migrate slightly below the reaction chamber and 
form a homogeneous front, and a minimum of 0.5 when few 
RBCs rise from the bottom typically going up just along one 
side of the column.16 Conventionally, a score between 3 and 4 
indicates a strong positive reaction, and a score between 0.5 
and 2 defines a weak positive reaction. One of the following 
anomalous conditions may occur, however: mixed field (MF), 
fibrin (FIB), or an undefined score, essentially due to the 
following:
• MF: two distinct cell populations (i.e., agglutinated and 
unagglutinated cells) are present.
• FIB: presence of fibrin may generate a positive test result 
at the bottom of the reaction chamber.
• Undefined score: few agglutinates are generated, and 
analyzer reading is indefinite.
When anomalous data are generated, the analyzer may 
require manual confirmation of test results. In case of a 
discrepancy between the test result and the prior known 
phenotype, the donor’s blood sample bag was retrieved and a 
new blood sample was sent to the reference laboratory of the 
blood transfusion service at the University Hospital A. Gemelli 
(Rome, Italy) for further serologic and molecular testing by 
sequence-specific primer (SSP) polymerase chain reaction 
(PCR).
Statistical Analysis
Descriptive tables were reported as absolute and relative 
frequencies. The accuracy of ORTHO Sera was evaluated by 
assessing sensitivity, specificity, and AUC, accounting for the 
clustering nature of repeated measures. A cross-classified 
mixed-effect logistic model was used for assessing the risk 
of measurement failure or misclassification as a measure 
of reliability. The model included only positive samples 
(i.e., samples that were single-dose or double-dose positive 
for the evaluated antigen). Replicates were hierarchically 
nested within cross-products of sessions and blood samples, 
representing a larger set of blood samples and sessions (i.e., 
the same blood sample would be used in multiple sessions, and 
the same session could include multiple samples). Therefore, 
both samples and sessions were treated as high-order (second) 
cross-level random effects. The antigen-specific combination 
(double-dose for a or b and single-dose [c = {a+, b+}]), the 
testing order of repetitions within each session (from 1 to 3), 
and the blood group system tested (Kidd, Duffy, MNS) each 
represented a fixed effect, which may not vary within each 
sample-session combination. Fixed effects may systematically 
contribute to the risk of measurement failure (misclassification) 
and explain part of the residual variability.
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Table 1. Technical description of the ORTHO Sera
Sera Clonality Method and cassette
Anti-Jka Human IgM monoclonal Ab
(P3HT7 clone)
DAT using OCD reverse 
diluent cassette
Anti-Jkb Human IgM monoclonal Ab
(P3.143 clone)
DAT using OCD reverse 
diluent cassette
Anti-Fya Human IgG monoclonal Ab
(DG-FYA-02 clone)
IAT using OCD IgG 
cassette
Anti-Fyb Human polyclonal IgG Ab IAT using OCD IgG 
cassette
Anti-S Human IgG monoclonal Ab
(P3S13JS123 clone)
IAT using OCD IgG 
cassette
Anti-s Human IgG monoclonal Ab
(P3YAN3 clone)
IAT using OCD IgG 
cassette
Ab = antibody; DAT = direct antiglobulin test; OCD = Ortho Clinical 
Diagnostics; IAT = indirect antiglobulin test.
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Null models were initially fit, which only included the 
random effects of sessions and samples, separately. Intra-
class correlation coefficients were used for estimating the 
proportion of residual variance dependent on sessions or 
samples, respectively. Fixed effects were then added iteratively 
or alternatively to the models and were further expressed as 
odds ratios (ORs).
A p value <0.05 was considered statistically significant. 
The analysis was performed using Stata software, version 13.1 
(StataCorp, College Station, TX).
Results
Accuracy of ORTHO Sera
Most of the ORTHO Sera displayed 100% sensitivity and 
specificity, except for anti-S (Table 2). This discrepancy was 
due to a single sample that yielded a false-negative result in one 
assessment with ORTHO Sera, but displayed a weak positive 
result in the remaining eight measurements. All ORTHO Sera 
displayed optimal AUC, equal to 1.00 in all cases except for 
anti-S (AUC 0.99).
Reliability of ORTHO Sera
Reliability has been confirmed (both intra- and inter-
assay). All repetitions gave the same intra-session and inter-
session data, except for a single anti-S serum assessment. 
Nevertheless, manual interpretation of the reaction score was 
necessary in some cases. This need was attributable to the 
presence of some anomalous results, especially for expression 
of MF, FIB, or undefined score.
Table 3 presents the frequency of anomalous results (38 of 
486 tests; 7.8%). Anomalous results only occurred in samples 
with any expression of antigens; those not expressing any 
antigen were always classified as negative by the analyzer, 
with no false-positive reactions. Manual interpretation was 
never necessary for results obtained with anti-Fyb and anti-s 
sera, whereas data generated with anti-Jkb needed manual 
interpretation in 14 of 81 cases (17.3%). Manual interpretation 
was necessary 15, 10, and 13 times in the first, second, and 
third repetitions, respectively (Table 4).
In the mixed model, sessions and samples contributed 
to 38 and 18 percent, respectively, of the overall variance of 
measurement failure outputs. Table 5 shows absolute frequency 
distribution across replicates. The order of repetitions within 
sessions was not associated with the risk of anomalous findings 
(OR 0.89, 95% CI 0.55–1.43; p = 0.62). The risk of anomalous 
findings was then compared between blood group systems 
tested and according to the antigen-specific status (double dose 
versus single dose) of each reagent-sample combination across 
sessions. Compared with the Duffy system, assay reactions for 
the MNS system had an OR of 1.38 (95% CI 0.13–14.28; p = 
0.88), and those for the Kidd system had an OR of 7.66 (95% 
CI 0.79–74.07; p = 0.08) for anomalous results. For single-
dose samples, while also accounting for the blood system 
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Table 2. Sensitivity, specificity, and AUC of the ORTHO Sera
Sera Sensitivity (%) Specificity (%) AUC
Anti-Jka 100 100 1.00
Anti-Jkb 100 100 1.00
Anti-Fya 100 100 1.00
Anti-Fyb 100 100 1.00
Anti-S 98 100 0.99
Anti-s 100 100 1.00
AUC = area under the receiver operating characteristics curve.
Table 3. Distribution of anomalous results by each individual 
ORTHO Sera reagent and type of anomaly
ORTHO Sera 
reagent US MF FIB
Automated 
readings Total
Anti-Jka 0 2 10 69 81
Anti-Jkb 0 14 0 67 81
Anti-Fya 0 4 1 76 81
Anti-Fyb 0 0 0 81 81
Anti-S 1 6 0 74 81
Anti-s 0 0 0 81 81
Total 1 26 11 448 486
US = undefined score: few agglutinates are generated; analyzer reading 
is indefinite; MF = two distinct cell populations (i.e., agglutinated and 
unagglutinated cells) are present; FIB = presence of fibrin may generate a 
positive test result at bottom of reaction chamber.
Table 4. Distribution of automated readings by order of repetition 
within sessions and reading output
Repetition US/MF/FIB Nil Weak positive Strong positive Total
1 15 1* 4 88 108
2 10 0 4 94 108
3 13 0 3 92 108
Total 38 1* 11 274 324
Fisher’s exact test: p = 0.85.
Table to include organic blood samples with reagent-specific positive status 
only.
*False-negative result with anti-S.
US = undefined score: few agglutinates are generated; analyzer reading 
is indefinite; MF = two distinct cell populations (i.e., agglutinated and 
unagglutinated cells) are present; FIB = presence of fibrin may generate a 
positive test result at bottom of reaction chamber.
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tested, anomalous results displayed an OR of 1.24 (95% CI 
0.39–4.00; p = 0.71) with double-dose samples (under the 
assumption of constant effect between a and b double-dose 
statuses). Sensitivity analyses compared the Jk effect with 
the effect of Fy and Ss, which were assumed constant. Results 
were similar (OR 6.49, 95% CI 0.93–45.28; p = 0.06).
Misclassification of ORTHO Sera with Potential 
Antigenic Variants
A critical sample was used in our validation plan for testing 
both the MNS and Kidd systems. The donor was a white man, 
whose RBCs were known to be group O, Rh phenotype of DCe/
cde, Jk(a–b+), and S+s+. During the assessment with ORTHO 
Sera anti-S, one single false-negative result was observed, and 
we found one single undefined scoring and scores of 0.5 in the 
remaining tests. The anti-s test gave no errors.
Assuming a possible qualitative or quantitative antigenic 
variant, we shipped a new sample to a reference laboratory. 
The sample was analyzed with both serologic typing (NEO 
Immucor automated system [Immucor, Norcross, GA]) and 
PCR-SSP (RBC-Ready Gene MNS kits [inno-train Diagnostik 
GmbH, Kronberg, Germany]). The tests yielded discordant 
results. More specifically, a strong positive score was found by 
assessing S antigen with serologic testing, whereas molecular 
biology testing was negative for the S allele.
Discussion
Our institution decided to implement an automated 
method for serologic typing in the local laboratory because of 
the increasing burden of multiple alloimmunizations against 
common RBC antigens in transfusion practice.5,7 It may be 
quite challenging to find donors for patients with complex 
alloimmunization,2 and the availability of many extensively 
typed donors would allow us to more easily and rapidly 
identify compatible RBC units for these patients.17,18
The current Italian recommendations suggest that the 
activity carried out in blood transfusion services must follow a 
validation and qualification process.14 In immunohematology, 
the purpose of the validation process is to ensure accuracy and 
reliability of tests. In our study, we performed a prospective 
method validation. After the first phase (IQ and OQ), we 
focused on PQ, using an experimental design entailing testing 
each factor in intra-series and inter-series triplicates, thus 
ensuring repeatability and reproducibility of the assay. The 
very stringent primary objective for accuracy (sensitivity and 
specificity of 100%) was accomplished for all tests except for 
anti-S serum, for which the sensitivity was 98%. Consistently, 
the use of the AUC, an additional index of accuracy, which 
combines both sensitivity and specificity, showed the 
maximum score of 1 for all sera, with the only exception of 
anti-S (AUC 0.99). Similar findings emerged from reliability 
analyses (i.e., analyzing both repeatability and reproducibility), 
in which results of all sessions were optimal for all sera, except 
for anti-S.
A weak score was generated in the critical sample over 
multiple anti-S assessments, so that further scrutiny was 
necessary. Molecular genotyping can support serologic testing. 
High-efficiency automated platforms currently allow us to 
extensively genotype donors and patients in blood banks or in 
the reference immunohematology laboratory.17,18 Genotyping 
could also predict weak or variant alleles, some of which may 
still generate challenges for the correct assessment of antigenic 
expression.19 In the suspicion of a possible S antigen variant, 
we consulted a reference laboratory for further serologic 
and molecular testing by PCR-SSP. These assays generated 
discordant results, because the serologic assessment with 
automated liquid phase was positive, whereas failure of gene 
amplification with selected primers was observed using molec-
ular biology. The MNS system has many rare phenotypes, 
characterized by specific antigenic expression patterns—the 
best known is the Miltenberger series.19 Discrepancy between 
serologic and molecular testing was suggestive for the presence 
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Table 5. Distribution of automated analyzer readings by session 
and reading output
Session US/MF/FIB Nil Weak positive Strong positive Total
1 3 0 1 32 36
2 1 0 3 32 36
3 1 0 0 35 36
4 12 0 0 24 36
5 14 0 0 22 36
6 0 0 0 36 36
7 4 0 2 30 36
8 3 1* 2 30 36
9 0 0 3 33 36
Total 38 1* 11 274 324
Fisher’s exact test for the equality of the proportions of UF/MF/FIB to Nil 
outputs over the row totals, across sessions: p < 0.001.
Table to include organic blood samples with reagent-specific positive status 
only.
*False-negative result with anti-S.
US = undefined score: few agglutinates are generated; analyzer reading 
is indefinite; MF = two distinct cell populations (i.e., agglutinated and 
unagglutinated cells) are present; FIB = presence of fibrin may generate a 
positive test result at bottom of reaction chamber.
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of a GYPB gene polymorphism close to the region of the PCR 
primer, which ultimately prevented in vitro amplification. A 
possible explanation may be the presence of a hybrid GYPA-
GYPB gene, secondary to unequal gene crossing-over, thus 
causing partial expression of S from the chimeric gene in the 
absence of the target region of GYPB primer. This hypothesis 
could only be confirmed by gene sequencing, however, which 
was not accessible at the time of this study. This evidence 
suggests that weak or variable hemagglutination requires 
molecular diagnostic investigation that can define a specific 
gene polymorphism using commercial validated in vitro 
diagnostic reagents; on the other hand, this approach may 
result in discovery of new undefined polymorphisms requiring 
gene sequencing for a complete definition. Further studies 
may be needed to define whether or not the combination with 
genotyping may be superior to hemagglutination, which is still 
widely considered the conventional serologic method.
Because of the observation of this false-negative result, 
some doubts were raised as to whether the validation of anti-S 
serum could be considered successful. As a potential solution 
to this issue, the Italian recommendations may be helpful, 
especially for managing the worst cases.14 Critical factors may 
sometimes emerge in routine activity and are now regarded 
as worst cases. According to the results of our validation, it 
can be hypothesized that an antigenic variant may be seen 
as a paradigmatic worst case. The recommendations clearly 
state that a worst-case test does not necessarily overthrow a 
process of validation because of the specific conditions under 
which validation is carried out, and that are clearly different 
from routine activity. It can be concluded that our validation 
was successful even for the anti-S serum.
Although in most cases the hemagglutination procedures 
are manually performed via test tube, this process has 
advantages and drawbacks. The incorporation of blood 
bank automation systems can help reduce human errors, 
improve standardization, alleviate heavy workload, and 
improve turnaround time.9–11 From occupational safety and 
health perspectives, biological safety of operators can also be 
improved by adopting automated systems. The minimal sample 
handling procedures reduce operator exposure to potentially 
hazardous biological materials. Moreover, a traceable database 
of laboratory records can be dynamically and cumulatively 
populated, since the image captured during interpretation of 
reactions can be permanently archived.11 Result interpretation 
may also be automated, whereas the manual assay still needs 
operator reading, which is inherently associated with subjective 
evaluation and broad interobserver variability.10 Nevertheless, 
ORTHO Sera sometimes needed manual interpretation for 
detecting anomalous results in our analytical evaluation, 
and this may lead to wastage of time, thus affecting work 
organization. Overall, anomalous findings could be observed 
in 38 of 486 (7.8%) tests, especially for MF (26 cases, 14 with 
anti-Jkb) and FIB (11 cases, 10 with anti-Jka). Multiple factors 
could theoretically explain the risk of obtaining anomalous 
results. Among the fixed conditions, the most obvious include 
the different performance of sera and the expression of blood 
group system antigens. The order of the three different intra-
session repetitions could also have an impact on analyzer 
or reagent performance. To evaluate randomly acting or 
systematic factors involved in the generation of anomalous 
findings also affecting reliability, we used a cross-classified 
mixed-effect logistic model. This model is intended to capture 
whether random effects should be considered in the analysis 
due, for example, to the unobserved randomly variable state 
of preservation and/or handling of RBC units (sample effect) 
or to non-controllable and largely unpredictable external 
conditions under which the session has been carried out, such 
as environmental temperature, operator’s accuracy, analyzer 
functionality, and so forth (i.e., session effect). Notably, none of 
the fixed factors, including order of replications, blood system 
tested, or antigen combination, was significantly associated 
with anomalous data.
The comparison of blood group systems needs further 
scrutiny. Compared with the reference Duffy system, no 
differences could be appreciated with MNS, whereas the 
Kidd system had some evidence, albeit statistically weak, of 
generating a larger number of anomalous results, both when 
compared to the other systems as separate entities, or as 
uniform entities. From a speculative perspective, the different 
behavior of the Kidd system antigens may be attributable 
to the fact that anti-Jk sera are monoclonal IgM antibodies 
that, unlike ORTHO Sera, do not necessitate anti-human 
globulin addition using reverse cassettes. Random factors 
may determine variability of anomalous findings, namely, the 
selection of blood samples (as RBC units) and the analytical 
performance of the session. Both factors were found to be 
associated with a substantial part of the risk of anomalous 
findings (p < 0.01), contributing 18% (intra-class correlation 
coefficient) and 38% to the overall variability, respectively. 
Taken together, the results of our analysis suggest that the 
frequency of anomalous results is in large part attributable 
to random (uncontrollable) factors. Although there is no 
immediate solution to reduce this component of variability, 
additional studies may be warranted for investigating specific 
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environmental factors that more likely may influence the 
random variability attributable to samples and sessions.
A major strength of our study is that we first carried out an 
experimental validation in an Italian transfusion center shortly 
after publication of the Italian recommendations.14 Validation 
studies are routinely carried out by pharmaceutical and plasma-
derivation industries, and the current recommendations 
actually suggest the use of an experimental design borrowed 
from the routine.14 The universally agreed-upon criterion of 
“exhaustive control” is currently represented by testing three 
consecutive batches, which is also regarded as the minimum 
requirement for process validation. Not fewer than three 
measurements for each of the identified stratification factors 
should be carried out, and we exactly matched this strategy in 
our evaluation.
The limited number of analyzed events should instead be 
considered a limitation of our study, especially for conducting 
the multivariable reliability analysis. This result is obviously 
attributable to the experimental design, which was based on 
the minimum number of samples required for validation, but 
also to reasonable cost restrictions for the availability and use 
of samples with a known phenotype.
Conclusions
In conclusion, we successfully carried out the validation 
of an automated CAT RBC typing method with Ortho Clinical 
Diagnostics’ ORTHO Sera against antigens in the Kidd, 
Duffy, and MNS blood groups systems. These sera displayed 
high accuracy and reliability and permit a viable automated 
procedure for rapid phenotyping of large numbers of donors.
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